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Abstract
Background: Acetylcholinesterase inhibitors (AChEIs) are widely used to delay cognitive decline in Alzheimer’s disease.
Observational studies in routine clinical practice have shown cognitive improvement in some groups of patients receiving
these agents but longitudinal trajectories before and after AChEI initiation have not previously been considered.
Objectives: To compare trajectories of cognitive function before and after AChEI initiation and investigate predictors of
these differences.
Method: A retrospective longitudinal study was constructed using data from 2460 patients who received AChEIs and who
had routine data on cognitive function (Mini-Mental State Examination; MMSE) before and after AChEI initiation.
Longitudinal MMSE change was modelled using three-piece linear mixed models with the following segments: 0–12 months
prior to AChEI initiation, 0–6 months and 6–36 months after initiation.
Results: MMSE decline was reversed (in that the slope was improved by an average 4.2 units per year, 95% CI 3.5–4.8)
during the 6-month period following AChEI initiation compared with the slope in the one year period before AChEI
initiation. The slope in the period from 6–36 months following AChEI initiation returned to the pre-initiation downward
trajectory. The differences in slopes in the 1 year period prior to AChEI initiation and in the 6 months after initiation were
smaller among those with higher MMSE scores at the time of AChEI initiation, among those who received a vascular
dementia diagnosis at any point, and among those receiving antipsychotic agents.
Conclusion: In this naturalistic observational study, changes in cognitive trajectories around AChEI initiation were similar to
those reported in randomised controlled trials. The magnitude of the difference in slopes between the 1 year period prior to
AChEI initiation and the 6 month period after AChEI initiation was related to level of cognitive function at treatment
initiation, vascular comorbidity and antipsychotic use.
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Introduction
Dementia is a major challenge because of its increasing
prevalence, substantial disability and high cost. Acetyl cholines-
terase inhibitors (AChEIs) remain the mainstay of pharmacother-
apy whose wide clinical use is largely justified by 3- to 6-month
improvements in cognitive and global function in Alzheimer’s
disease with a Cochrane review estimating a 1.37 (95% CI 1.13,
1.61) Mini-Mental State Examination (MMSE) score improve-
ment at 6 months after AChEI initiation [1]. Randomised
controlled trials are optimally designed to quantify efficacy and/
or effectiveness of interventions but tend to have insufficient
power, even when combined, to describe individual variability in
response, even less so predictors of good or poor response.
Furthermore, trial inclusion and exclusion criteria limit generali-
sability of findings to ‘real world’ clinical settings. Findings from
observational clinical studies of AChEI response have varied
including an MMSE improvements of 0.5 points [2] and a 0.5
point decrease [3] at 6 months after treatment initiation. However,
observational cohort studies to date have only investigated
cognitive response to AChEIs from the point of drug initiation
and have not taken into account the preceding trajectory of
cognitive decline.
This study made use of a routine clinical data resource sourced
from a large provider of dementia care, describing and comparing
trajectories in MMSE scores before and after AChEI initiation
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followed by an investigation of factors associated with these
changes in slope.
Methods
Ethics Statement
The study was approved as an anonymized dataset for
secondary analysis by the Oxfordshire Research Ethics Committee
C (reference 08/H0606/71).
Study setting and data source
A retrospective observational study was conducted using data
from the South London and Maudsley NHS Foundation Trust
(SLAM) Biomedical Research Centre (BRC) Case Register. This
data resource has been described in detail [4] and has supported a
range of analyses [5,6]. In summary, it provides researcher access
to full but anonymised copies of electronic medical records from
SLAM, Europe’s largest mental healthcare provider covering a
geographic catchment of 1.2 million residents and delivering a
comprehensive range of mental health services, including demen-
tia assessment and treatment. Data are currently archived on over
220,000 cases with a range of mental disorders.
Study cohort
Using keyword searching functionality in the SLAM BRC Case
Register, records were retrieved on all patients who had received
AChEI drugs (donepezil, rivastigmine or galantamine) during
2003–2010 and information was manually retrieved including all
recorded measures of cognitive function within 12 months before
and 36 months after AChEI initiation. In UK clinical practice,
AChEI agents were licensed for the treatment of Alzheimer’s
disease during the period of observation; however, in routine
clinical practice there was flexibility in interpretation of this
diagnosis – for example, in relation to comorbidity with vascular
dementia. The sample for this analysis was of all people receiving
these agents and recorded diagnoses were not applied as
inclusion/exclusion criteria. In British dementia treatment servic-
es, cognitive function continues to be primarily monitored in
routine clinical practice using the Mini-Mental State Examination
(MMSE) [7] a 30-point measure of global function in wide use. In
order to assess cognitive decline before and after AChEI initiation,
the analysed sample was restricted to those with at least one
MMSE score before AChEI initiation and one score afterwards.
Date of AChEI initiation was defined as the first receipt of any of
the three agents, regardless of dose.
Measurements
All MMSE scores during the 4-year observation period were
used to model cognitive trajectories. Entries describing scores with
below-30 denominators due to missing items were corrected by the
number of missing items. For example, if a 28 denominator was
cited, 2 points were added to the numerator for analysis. In
addition, the MMSE score closest to the date of AChEI initiation
was categorised as a covariate into standard groups (25+, 21–24,
10–20, ,10) for stratified analyses. The following additional
information was extracted from the record using both structured
fields and manual text review: age (at AChEI initiation), sex,
ethnicity (white vs. other), and marital status (married/cohabiting
vs. other). Highest educational qualification was categorised into
three groups: i) no qualification, ii) standard qualification (O-level,
implying school leaving age of 16), iii) advanced qualification (A-
level or university, implying school leaving age above 16). As a
proxy measure of socio-economic status, area-level deprivation
scores in 2007 were available through an anonymised link created
between lower super output area residence code (an address unit
representing between 1500–2000 residents) and summary data for
that area from 2001 UK Census output. The index of multiple
deprivation is derived from seven domains: income, employment,
health, education, housing and services, crime, and environment
(Index of Multiple Deprivation, 2007). Patients not infrequently
received more than one diagnosis during the course of their
treatment and the presence of Alzheimer’s disease, vascular
dementia and Lewy body dementia diagnoses were ascertained as
non-exclusive binary variables. The presence or not of a vascular
dementia diagnosis at any point was considered as a proxy
measure of comorbid cerebrovascular disease. Recorded medica-
tion was categorised into the following groups: antidepressants,
antipsychotics, diabetes drugs, gastrointestinal drugs, lipid regula-
tors, cardiovascular disease drugs, other central nervous system
drugs, respiratory drugs, and antiplatelet, fibrinolytic or anticoag-
ulant drugs.
Statistical analysis
The analysed cohort was initially compared to the wider cohort
of all patients receiving AChEI treatment. The trajectory of
MMSE scores in the sample was initially modelled for observa-
tional purposes using a non-parametric regression method: the
Generalised Additive Model for Location, Scale and Shape
(GAMLSS) introduced by Rigby and Stasinopoulos [8]. This
study used at least one single point of MMSE before and at least
one MMSE point after drug initiation. After visual observation of
this curve, a parametric piecewise linear mixed model, equivalent
to a linear regression with interaction terms was used. For analysis
the observation time was divided into the following three segments
within which MMSE slopes (rate of change in MMSE scores)
satisfactorily approximated linearity: i) 12 months prior to AChEI
initiation; ii) 0 to 6 months after initiation; iii) 6 to 36 months after
initiation. Slope differences were calculated between each of the
three time segments (12 months prior, 0–6 months after and 6–36
after drug initiation). Time in the mixed models was defined as the
number of years since the AChEI initiation date, with negative
values for the pre-initiation period. Two-way interaction terms
were used in the linear mixed estimations to estimate slope
differences between time periods and were modelled before and
after (Slope difference = coefficient of time* before-after indica-
tor). Three-way interaction terms were tested to investigate
modification of slope differences by covariates (Modification of
slope difference = Coefficient of time*before-after indicator*cov-
ariate). All analyses were carried out using R software.
Results
Within the years of data examined, a total of 3416 patients had
received AChEI treatment of whom 2460 had sufficient MMSE
scores for analysis. Characteristics of these samples are described
and compared in Table 1; in summary, there were no observable
differences and the analysed sample appeared representative. For
the analysed sample within the observation period, data on a total
of 10,669 MMSE scores were available, with a mean 4.3 (SD 0.51)
scores per patient. The mean MMSE score at AChEI initiation
was 19.9 (SD 5.1).
Figure 1 displays non-parametric (GAMLSS) models of MMSE
slope trajectories before and after AChEI initiation for the whole
sample and stratified by MMSE strata at treatment initiation. It
was observed that a pre-treatment decline was followed by an
improvement over the 6 months after treatment, which in turn was
followed by continued decline. For the full cohort, following the
initial score improvement the MMSE at treatment initiation was
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reached again after 10 (95% CI 7–12) months. An additional
observation was that the 6-month improvement became progres-
sively more marked with lower MMSE at AChEI initiation.
From parametric (piecewise linear mixed) models, the three
MMSE slopes were calculated to be a decline of22.45 (95% CI2
2.88, 22.02) points per year during the 12 months prior to AChEI
initiation, an increase of 1.73 (1.34, 2.12) points per year during
the 6 months after initiation, and a decline of 22.68 (22.86, 2
2.50) points per year during the 6–36 month period. Differences in
slopes for the whole sample and by MMSE strata are displayed in
Table 2. For the whole sample significant slope improvements
were observed over 0–6 months compared to those in the 12
months pre-treatment; however, no significant slope difference was
found comparing the 6–36 month and pre-treatment periods. As
had been suggested in non-parametric models, the 0–6 month
slope improvement was substantially more marked in patients with
lower MMSE scores at AChEI initiation. In those with lowest
(below 10) scores, 6–36 month MMSE slopes were also improved
compared to those in the pre-treatment period, although
confidence intervals were wide.
Considering the 6-month MMSE slope improvement, further
interactions with socio-demographic and clinical covariates are
summarized in Table 3. No significant differences were found in
slope improvement between comparison periods by age, gender,
deprivation, education or marital status. However, improvement
in MMSE slope after treatment initiation was significantly stronger
in non-white ethnic groups. It was weaker in patients who had
received a vascular dementia diagnosis, but no modification was
found by presence or not of a Lewy body dementia diagnosis. The
same interactions with co-administered medications are summa-
rised in Table 4: use of antipsychotic agents, gastrointestinal drugs
and anti-platelet, fibrinolytic or anticoagulant agents were all
associated with a smaller slope difference between time periods.
When analyses were repeated restricting medications to those
Table 1. Comparison of all patients received AChEI treatment (full cohort) and the analysed sample.
Characteristic Full cohort (n =3416) Analysed sample* (n =2460)
MMSE score at drug initiation
25 and over 705 (20.6%) 529 (21.5%)
21–24 913 (26.7%) 706 (28.7%)
20–10 1633 (47.8%) 1161 (47.2%)
less than 10 165 (4.8%) 64 (2.6%)
Age at AChEI initiation
,65 years 123 (3.6%) 89 (3.6%)
65–79 years 1390 (40.7%) 1028 (41.8%)
80+ years 1903 (55.7%) 1343 (54.6%)
Gender
Male 1208 (35.4%) 870 (35.4%)
Female 2207 (64.6%) 1590 (64.6%)
Ethnicity
White 2808 (83.8%) 2044 (84.1%)
Non-white 543 (16.2%) 386 (15.9%)
Marital status
Married/cohabiting 1332 (41.4%) 953 (40.4%)
Divorced/single/separated or widowed 1885 (58.6%) 1404 (59.6%)
Education
No qualifications 784 (33.4%) 630 (35.1%)
Standard qualification 451 (19.2%) 352 (19.6%)
Advanced qualification 1114 (47.5%) 811 (45.2%)
Deprivation quintile
1 (most deprived) 741 (22.0%) 521 (21.5%)
2 689 (20.5%) 466 (19.2%)
3 638 (19.0%) 459 (18.9%)
4 889 (26.4%) 668 (27.5%)
5 (least deprived) 408 (12.1%) 314 (12.9%)
Type of dementia diagnosed at any point
Alzheimer’s disease 2760 (80.8%) 2050 (83.3%)
Vascular dementia 673 (19.7%) 491 (19.9%)
Lewy body dementia 118 (3.4%) 89 (1.8%)
*Sufficient MMSE data (i.e. at least one score within 12 months before and one score within 36 months after treatment initiation) and measurement restricted to 12
months before and 36 months after treatment initiation.
doi:10.1371/journal.pone.0109484.t001
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recorded before AChEI initiation, the interaction terms for
antipsychotics (coefficient = 0.16, P-value = 0.66) and gastrointes-
tinal drugs (coefficient = 0.28, P-value = 0.54) were substantially
reduced but the coefficient for anticoagulant drug use remained
similar (coefficient was 0.58, p= 0.09).
Discussion
In this large observational study of routine AChEI treatment
provision, we investigated the difference between pre- and post-
treatment trajectories of cognitive function and predictors of these
slope differences. On average, a significant improvement was
observed in the MMSE trajectory by 4.16 points per year in
patients who received AChEIs during the 6 months after treatment
compared with the 12 months before treatment. However, MMSE
slopes after 6 months were near-identical to pre-treatment slopes
in most cases. When stratified by MMSE score at AChEI
initiation, people with higher scores (MMSE scores 21 or over)
at the time of AChEI initiation on average had a smaller
improvement (figure 2) than people with lower scores (MMSE
score ,21) at the time of AChEI initiation (figure 3). Most socio-
demographic factors investigated were not predictors of the initial
slope change, including age at treatment initiation, gender, and
education. However, non-white ethnic groups who received
AChEI treatment responded significantly better, with a slope
improvement more marked than their counterparts by 0.5 points
per year. In terms of diagnosis, patients with vascular dementia
recorded at any point responded less well (by 0.4 MMSE points
per year) than those without this diagnosis. Patients who received
antipsychotics, gastrointestinal drugs, and anti-platelet, fibrinolytic
or anticoagulant agents at any point were found to have a weaker
response to AChEIs, although only the last of these persisted as an
effect modifier when pharmacotherapy was restricted to that
recorded before AChEI treatment initiation.
Randomised controlled trials of AChEI treatment in Alzhei-
mer’s disease specifically have demonstrated an improvement in
MMSE score in the intervention arm at 6 months. In our
naturalistic sample from routine clinical practice, the pattern was
interestingly similar with a slope of 1.73 MMSE points per year
improvement over the 6 months after treatment initiation. As
previously stated, observational studies to date have only described
slopes following treatment, but have given rise to heterogeneous
findings. One UK study found an improvement of 1.8 MMSE
points per year among 939 patients with a mean follow up period
of 4 months [9]. However, another study found no change over 6
months in people receiving donepezil [10], a finding that
concurred with other studies of donepezil in clinical practice over
the same period [11], suggesting stabilisation of cognitive decline
rather than improvement over the first 6 months. A Spanish
clinical cohort found over a 6 month period that the MMSE score
improved significantly over baseline [12], but an Italian study
found a one point per year decline for all three AChEI agents,
although the slope did not show a statistically significant difference
from a zero slope [3].
Figure 1. Non-parametric (GAMLSS) models of MMSE trajecto-
ries before and after AChEI initiation for all patients who
received AChEIs (n =2460), (AChEI initiation date is defined as
time 0).
doi:10.1371/journal.pone.0109484.g001
Table 2. Difference in unadjusted and adjusted MMSE decline rate per year for different baseline MMSE scores.
Unadjusted rate Adjusted rate$
Time periods
compared Baseline MMSE
Differences in slope,
MMSE points per year 95% CI
Differences in slope,
MMSE points per year 95% CI
Total sample 4.19 3.52 to 4.85 4.16 3.49 to 4.83
0 to 6 months
post-treatment vs.
12 months pre-treatment
25 and over 0.52 20.66 to 1.70 0.49 20.69 to 1.67
21–24 2.96 2.02 to 3.91 2.96 2.37 to 3.55
10–20 5.93 4.97 to 6.89 5.9 4.94 to 6.86
,10 9.4 4.83 to 14.0 9.74 5.13 to 14.40
Total sample 20.22 20.65 to 0.21 20.23 20.66 to 0.20
6 to 36 months
post-treatment vs.
12 months pre-treatment
25 and over 21.36 22.09 to 20.63 21.37 22.10 to 20.64
21–24 20.81 21.42 to 20.20 20.80 22.72 to 1.12
10–20 0.09 20.56 to 0.74 0.09 20.56 to 0.74
,10 3.37 0.27 to 6.47 3.59 0.45 to 0.73
$adjusted for age at AChEI initiation, gender, marital status, education, ethnicity and deprivation.
doi:10.1371/journal.pone.0109484.t002
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Several studies have suggested that MMSE score at baseline is a
predictor of response to AChEIs [13], although a Cochrane review
concluded that all three agents were efficacious for mild to
moderate Alzheimer’s disease [1]. Studies have also shown that as
AD progresses, AChE activity can be reduced by up to 67% of
normal levels in the temporal lobe and hippocampus [14]. An
observational study found a better cognitive response to AChEI
treatment in patients with moderate dementia (MMSE 10–20)
compared to those with mild dementia (MMSE 21 or over) at
baseline [9]. At least part of the difference in apparent response
may relate to the underlying rate of cognitive decline at different
stages of dementia, with more detectable effects at later stages in
the context of accelerated progression [9]. The finding that those
with moderate dementia do better, in terms of cognitive
improvement, than those with mild dementia replicates the
findings of other studies of routine clinical populations [15]. This
might be explained by differences in the meaning of a point
difference in MMSE across its distribution: i.e. a difference may be
more readily detected at moderate than mild dementia ranges.
Furthermore, it is possible that there is a greater reversible
cholinergic deficit in patients with moderate dementia [9]. Post-
mortem studies in AD have shown measures of cholinergic
function to correlate with global cognitive test scores [16], and
AChEIs may have a greater effect on a larger cholinergic deficit
[9].
Cognitive improvement following AChEI treatment was found
to be stronger in patients from non-white compared to white
ethnic groups. In the geographic catchment covered by SLAM,
non-white elders are predominantly African-Caribbean, although
it was not possible to break down non-white groupings into more
specific subtypes. Higher prevalence of dementia has been found
in older African- Caribbean compared to white UK-born residents
as well as a dementia onset in African-Caribbean patients nearly,
on average, 8 years younger than their white counterparts [17].
Table 3. Socio-demographic/clinical characteristics and MMSE slope differences before and 6 months after AChEI initiation.
Predictor Slope difference Coefficient Standard error p-value
Unstratified (total sample) 4.16
Age at AChEI drug initiation
65–69 4.14 0.002 (per year increase) 0.01 0.71
70–74 4.15
75–79 4.16
80–84 4.17
85–89 4.18
90+ 4.19
Gender
Male 4.10 Ref.
Female 4.21 0.11 0.2 0.42
Ethnicity
White 4.09 Ref
Non-white 4.60 0.51 0.2 0.009
Deprivation quintile
1 (most deprived) 4.20 0.01 0.01 0.53
2 4.22
3 4.19
4 4.14
5 (least deprived) 4.09
Marital status
Married/cohabiting 3.98 Ref.
Not cohabiting 4.28 0.3 0.1 0.08
Education
No qualification 4.08 0.04 0.13 0.65
O/Level 4.13
A/level or University 4.16 .
Any vascular dementia diagnosis
Present 3.80 20.41 0.21 0.04
Not present 4.19 Ref.
Any Lewy body dementia diagnosis
Present 4.22 0.07 0.44 0.87
Not present 4.16 Ref.
doi:10.1371/journal.pone.0109484.t003
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Table 4. Co-administered medication and MMSE slope differences before and 6 months after AChEI initiation.
Predictor Slope difference Coefficient Standard error p-value
Antidepressants
Received 4.21 0.06 0.11 0.81
Not received 4.15 Ref.
Antipsychotics
Received 3.73 20.73 0.25 0.008
Not received 4.46 Ref.
Other CNS drugs
Received 4.14 20.22 0.12 0.21
Not received 4.36 Ref.
Diabetes drugs
Received 4.22 0.12 0.21 0.51
Not received 4.14 Ref.
Gastrointestinal drugs
Received 3.91 20.34 0.12 0.006
Not received 4.25 Ref.
Lipid lowering agents
Received 4.37 0.35 0.24 0.13
Not received 4.12 Ref.
CVD drugs
Received 4.21 0.1 0.11 0.94
Not received 4.11
Anti-platelet, fibrinolytic and anticoagulant agents
Received 4.01 20.33 0.12 0.02
Not received 4.34 Ref.
Respiratory system drugs
Received 4.33 0.22 0.51 0.67
Not received 4.11 Ref.
doi:10.1371/journal.pone.0109484.t004
Figure 2. Non-parametric (GAMLSS) models of MMSE trajectories before and after AChEI initiation for those patients whose MMSE
scores at the time of AChEI initiation were: (A) between 25 and 30, (B) between 21 and 24, (AChEI initiation date defined as time 0).
doi:10.1371/journal.pone.0109484.g002
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Vascular dementia is likely to be a more common feature in
African-Caribbean elders because of their well-recognised higher
risk of stroke, hypertension and diabetes. However, neither
vascular disease nor a younger age of onset are likely to account
for the better response to AChEI treatment because, in the sample
as a whole, age of onset was not associated with treatment response
and vascular dementia was associated with a less marked response.
This finding therefore requires replication and further investiga-
tion. One possible explanation might lie in more supportive family
structures and consequent improved treatment adherence.
Considering dementia diagnoses as covariates, the presence of
vascular dementia was associated with a significantly weaker
difference between pre- and post-treatment slopes. Previous
longitudinal studies in dementia have found accelerated cognitive
decline associated with cerebral infarcts and congophilic angiop-
athy [18], and slower progression associated with diabetes, but no
associations with hypertension and hypercholesterolemia [19].
However, these findings for cognitive decline in dementia do not
necessarily predict treatment response. Diagnoses recorded were
those applied in routine practice by clinicians and should not be
assumed to generalise to research diagnoses. However, the finding
of a lower AChEI response in cases receiving a vascular dementia
diagnosis may reflect a weaker cholinergic deficit in this group
[20], or might possibly reflect a diagnosis made or altered on the
basis of worse treatment response (reverse causality). Although a
diagnosis of vascular dementia was associated with a smaller
response to AChEI treatment, there was only limited evidence for
the same pattern of association with specific cardiovascular
medication groups apart from anticoagulant and related agents,
which were also associated with reduced likelihood of response.
Since aspirin is likely to be the most common agent in this
category, the effect modification may primarily relate to the
presence of cerebrovascular disease rather than risk factors for this.
Analyses of other medications found that receipt of gastrointes-
tinal drugs, anticoagulant agents, and antipsychotic agents was
associated with smaller MMSE slope differences after AChEI
initiation. In a pooled analysis of the placebo arms of six AD trials,
antipsychotic use was found to be associated with significantly
lower cognitive function [21] and Lopez- Pousa et al (2006)[12]
found that patients treated with atypical antipsychotics had a
greater risk of mortality, although as with other studies of this kind,
it is difficult to conclude whether the mortality was a direct
consequence of antipsychotic use or secondary to the symptom or
behavioural profiles for which they were prescribed. Other studies
have found an association between the use of atypical antipsy-
chotic drugs and a greater frequency of cerebrovascular outcomes
[22]. Although our observations might reflect adverse effects of
antipsychotic agents on cognition accounting for the reduced
AChEI response, this effect modification could not be demon-
strated when restricted to exposure in the pre-AChEI period. Thus
it was not possible to exclude the possibility that antipsychotic
agents were being used to treat a more severe dementia syndrome
which had failed to respond to AChEI treatment.
Our study found that a better improvement in MMSE score
after AChEI treatment was present in patients of non-white
ethnicity, those without vascular dementia diagnosis at any point,
those not receiving antipsychotic agents, those not receiving
gastrointestinal drugs, and those not receiving anti-platelet,
fibrinolytic and anticoagulant agents. However, although these
MMSE trajectory differences were statistically significant, they
were relatively small in size and detectable as a group-level effect
over a large sample. It cannot therefore be concluded from these
data that they were sufficiently clinically significant to warrant
alterations in routine practice – this would require a longer-term
comparative evaluation of subsequent disease course and of
broader outcomes beyond cognitive function, which was outside
the scope of this study.
This study had considerable advantages over other comparable
cohorts, not only in the data available on pre-treatment MMSE
slopes but also in the substantial accumulated follow-up –
approximately 5900 person years in total (1700 person years
pre-treatment, 4200 post-treatment). Although case registers have
a long history and are widely used in mental health and dementia
research, we believe that the SLAM BRC Case Register is likely to
be the largest in Europe at least containing the necessary depth of
data for this type of study [4], other data resources tending to be
confined to summary or administrative variables rather than full
text records. The ‘before and after’ comparison is a powerful
means to limit confounding because the effect is inferred from
pooling within-individual comparisons (i.e. are matched for the
characteristics of the individual). The key potential confounding
factors in such a comparison are other features which have also
varied before and after treatment and are therefore substantially
more limited.
The key limitations concern the observational nature of the
study and the fact that data were from routine clinical care rather
Figure 3. Non-parametric (GAMLSS) models of MMSE trajectories before and after AChEI initiation for those patients whose MMSE
scores at the time of AChEI initiation were: (A) between 10 and 20, (B) between 0 and 10, (AChEI initiation date defined as time 0).
doi:10.1371/journal.pone.0109484.g003
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than obtained through a research study. However, errors in
measurement (for example the limitation of the MMSE in
comparison with more in-depth measures) will have obscured
rather than exaggerated associations of interest. Considering
sample representativeness, under the UK National Health Service
structure, SLAM provides all mental health care (including
dementia services) to its geographic catchment. Because there
was minimal AChEI prescription by general practitioners during
the period these data were collected, the sample represents all
people in the catchment receiving these agents. However, people
who receive AChEI intervention are only a subset of cases with
dementia in the community. Perceived likelihood of a given
outcome might have had an influence on inclusion, although this is
unlikely because there are no commonly agreed factors predicting
good or poor response (and indeed relatively few predictors of
response were found in our analyses). Considering pre-treatment
MMSE slopes, more precipitous decline might predict someone
with dementia coming to medical attention and it is possible that
this accounted at least in part for the slope improvement around
AChEI initiation In terms of loss to follow-up, mortality rates were
relatively low (26.8% by the end of the observation period).
Although analyses were of all cognitive data during the
observation period rather than restricted to those during AChEI
treatment, withdrawal from treatment would render discharge and
loss to follow-up more likely. Withdrawal from AChEIs is also an
issue for the primary analyses. In long-term studies of AChEI, high
rates of withdrawal from treatment have been reported [23]. This
causes difficulties in interpreting the results. The reasons for
dropout are complex and may include side effects, deterioration,
co-morbidity, but also a wish to switch to other drugs as they
become available. In the study by Wallin [23], the one-year
completion rate was 66%, while in other studies it has ranged from
33 to 92% [24,25]. In our study, 38% of patients received AChEIs
for the entire 36 month period after initiation. Among the
remaining 62% of patients, the mean (SD) AChEI exposure
duration was 14 (9) months.
Another limitation in this study was related to statistical
concepts. We used models that assumed that the MMSE has
linear scaling properties, which is an assumption that has
frequently been argued. One study [26] found curvilinear scaling
properties for the MMSE and other common global cognitive
tests. The shape for that curve was very similar to a curve
published by Proust-Lima and colleagues using a very different
methodology [27]. However, we did not use this methodology
because we did not have item-level MMSE data available.
In summary, in this naturalistic observational study, changes in
cognitive trajectories around AChEI initiation were interestingly
similar to those reported in randomised controlled trials. Clearly
the effect of these agents on cognitive decline in dementia has to be
concluded from the trial evidence. However, sample sizes in trials
are too small, even when combined, to provide data on predictors
of good/poor response to treatments. Addressing these questions
relies on large observational datasets and our findings suggest that
the growing use of electronic health records, coupled with the
ability to extract automated data from text fields on routine
measures such as the MMSE, provides important potential
opportunities for advancing research into routine interventions
and their real-world outcomes.
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